Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Rituximab in Active Graves Ophthalmopathy
2009-014361-14Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in Graves Orbitopathy (GO) and Graves' disease, sponsored by Policlinico Gemelli. Primary endpoint: Feasibility of intralesional rituximab injection. Started Dec 2009; status: completed.
02
Drugs
rituximab
03
Conditions
Graves Orbitopathy (GO)Graves' disease
Beyond the preview
Go deeper on 2009-014361-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014361-14.